Literature DB >> 11809684

Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation.

Sylvie Lamy1, Denis Gingras, Richard Béliveau.   

Abstract

Vascular endothelial growth factor (VEGF) receptors (VEGFR) play a major role in tumor angiogenesis and, thus, represent attractive targets for the development of novel anticancer therapeutics. In this work, we report that green tea catechins are novel inhibitors of VEGFR-2 activity. Physiological concentrations (0.01-1 microM) of epigallocatechin-3 gallate, catechin-3 gallate, and, to a lesser extent, epicatechin-3 gallate induce a rapid and potent inhibition of VEGF-dependent tyrosine phosphorylation of VEGFR-2. The inhibition of VEGFR-2 by epigallocatechin-3 gallate was similar to that induced by Semaxanib (SU5416), a specific VEGFR-2 inhibitor. The inhibition of VEGFR-2 activity by the catechins displayed positive correlation with the suppression of in vitro angiogenesis. These observations suggest that the anticancer properties of green tea extracts may be related to their inhibition of VEGF-dependent angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809684

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Green tea phenolics inhibit butyrate-induced differentiation of colon cancer cells by interacting with monocarboxylate transporter 1.

Authors:  S Sánchez-Tena; P Vizán; P K Dudeja; J J Centelles; M Cascante
Journal:  Biochim Biophys Acta       Date:  2013-08-28

Review 3.  Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives.

Authors:  Dale G Nagle; Daneel Ferreira; Yu-Dong Zhou
Journal:  Phytochemistry       Date:  2006-07-31       Impact factor: 4.072

Review 4.  Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.

Authors:  Brahma N Singh; Sharmila Shankar; Rakesh K Srivastava
Journal:  Biochem Pharmacol       Date:  2011-07-30       Impact factor: 5.858

5.  Cancer Phytotherapy: Recent Views on the Role of Antioxidant and Angiogenesis Activities.

Authors:  Mahmood Bahmani; Hedayatollah Shirzad; Najmeh Shahinfard; Laaleh Sheivandi; Mahmoud Rafieian-Kopaei
Journal:  J Evid Based Complementary Altern Med       Date:  2016-06-22

6.  Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion.

Authors:  In-hae Kwak; Yun-Hye Shin; Myeongdeok Kim; Hyun-Young Cha; Hyun-Ja Nam; Bok-Soon Lee; S C Chaudhary; Ki-Soo Pai; Jae-Ho Lee
Journal:  Exp Mol Med       Date:  2011-02-28       Impact factor: 8.718

7.  Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.

Authors:  Jianming Lu; Keqiang Zhang; Sangkil Nam; Richard A Anderson; Richard Jove; Wei Wen
Journal:  Carcinogenesis       Date:  2009-12-07       Impact factor: 4.944

Review 8.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

9.  Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.

Authors:  Hoyee Leong; Priya S Mathur; Geoffrey L Greene
Journal:  Breast Cancer Res Treat       Date:  2008-09-28       Impact factor: 4.872

10.  (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.

Authors:  Bao-He Zhu; Wen-Hua Zhan; Zheng-Rong Li; Zhao Wang; Yu-Long He; Jun-Sheng Peng; Shi-Rong Cai; Jin-Ping Ma; Chang-Hua Zhang
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.